This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q23.4 | Special Copayment Reduction: V147 (rare disease) |
| B. Synonyms | Hypoplastic left heart syndrome | Atresia or marked hypoplasia of the aortic orifice and valve, with hypoplasia of the ascending aorta and defective development of the left ventricle (with mitral valve stenosis or atresia) |
| C. Adult onset | Likelihood of first presentation in adulthood: very low — HLHS is the most critical congenital heart malformation, presenting in the neonatal period, and without treatment death occurs within days to weeks after birth. Currently, some patients reach adulthood with staged palliative surgery (Norwood→Glenn→Fontan), but continued specialist follow-up is needed because of single-ventricle physiology. |
| 1. History | 1952 first description by Lev; 1983 development of Norwood staged palliative surgery; 1985 report of heart transplantation. |
| 2. Causes | Hypoplasia of the entire left heart inflow and outflow tract in fetal life; atresia or stenosis of the aortic and mitral valves; insufficient development of the left ventricle. |
| 3. Genetics | Multifactorial inheritance; associated with NOTCH1, NKX2.5, HAND1, GJA1; increased frequency in Turner syndrome (45,X). |
| 4. General epidemiology | About 1 in 10,000 births; neonatal death if untreated; increased survivors since the introduction of staged palliative surgery. |
| 5. Pathophysiology | Loss of left heart function → right ventricle alone supports mixed systemic and pulmonary circulation → ductus-dependent systemic circulation → pulmonary vascular resistance is important. |
| 6. Symptoms | Neonatal period: cyanosis, shock (after ductal closure); after Fontan: exercise intolerance, protein-losing enteropathy, arrhythmias. |
| 7. Signs | Neonatal shock; weak, rapid pulse; single S2; pulse improvement after PGE1 administration; ascites and edema after Fontan. |
| 8. Screening | Fetal echocardiography (18–22 weeks of gestation) is key; pulse oximetry newborn screening (SpO2 <95%); delivery planning after prenatal diagnosis. |
| 9. Diagnosis | Fetal/neonatal echocardiography is standard; cardiac CT for preoperative vascular anatomy; cardiac catheterization for pressure measurement before and after Fontan. |
| 10. Treatment | Norwood (stage 1) → bidirectional Glenn (stage 2) → Fontan (stage 3) staged palliative surgery; heart transplantation is the final option. |
| 11. Prognosis | 10-year survival after Norwood→Glenn→Fontan about 60–70%; complications of single-ventricle Fontan physiology determine long-term prognosis. |
| 12. Prevention | Planned delivery after prenatal diagnosis by fetal echocardiography; readiness for immediate PGE1 administration; home monitoring after Norwood. |
| 13. References | 10 major clinical guidelines and original papers |
Since it was first systematically described by Lev in 1952, hypoplastic left heart syndrome (HLHS) was for a long time synonymous with an 'untreatable' congenital heart malformation. Later, in 1958, Noonan and Nadas compiled clinical cases and established the name of this syndrome. Even in the 1960s–70s, when open-heart surgery advanced, corrective surgery was impossible for this malformation, in which the left ventricle is so severely hypoplastic that it cannot support the systemic circulation, and most patients died after diagnosis without any surgical attempt.
The history of HLHS treatment changed when William Norwood first succeeded with staged palliative surgery (Norwood procedure, stage 1) in 1983. The Norwood procedure reconstructs the main pulmonary artery into the aorta so that the right ventricle supports the systemic circulation, and supplies pulmonary blood flow through a modified Blalock-Taussig shunt (BTS). Early survival was low, but technical improvements over the following decades raised stage 1 survival to 70–80%. The 1991 Sano modification (Norwood-Sano procedure) used a right ventricle-to-pulmonary artery conduit (RV-PA conduit) instead of a BTS, improving diastolic pulmonary artery perfusion.
The stage 2 bidirectional Glenn shunt (BDG; described by Glenn in 1958 and later applied bidirectionally) and the stage 3 Fontan procedure (first reported by Fontan and Baudet in 1971 and later refined) completed the three-stage palliative system for single-ventricle physiology. In Korea, staged surgery for HLHS began to be performed at specialized pediatric cardiac surgery centers from the late 1990s, and patients are now managed under Special Copayment Reduction (V147) registration.
HLHS is a serious congenital heart malformation characterized by global hypoplasia of the fetal left heart structures—the mitral valve, left ventricle, aortic valve, and ascending aorta. It is not a single entity; several anatomical subtypes form a spectrum, showing varying severity depending on the degree of involvement.
The most common anatomical type is aortic atresia + mitral atresia, which is the most severe, followed by aortic atresia + mitral stenosis and aortic stenosis + mitral stenosis. In aortic atresia, there is no antegrade flow into the ascending aorta, so the ascending aorta becomes extremely narrow (1–2mm), and even coronary blood flow is supplied retrogradely.
Fetal hemodynamic theory: the currently prevailing hypothesis is 'flow-dependent development', according to which the left heart fails to develop adequately if blood flow to the left heart decreases for any reason during fetal development. Proposed causes include premature restriction of the foramen ovale, reduced inflow due to mitral valve dysplasia, and reduced outflow due to aortic stenosis. Progression of intrauterine aortic stenosis to HLHS is partly supported by animal experiments and clinical data.
As for genetic contribution, most cases are sporadic, but familial clustering has also been reported, and variants in several genes such as NOTCH1, GJA1, NKX2.5, HAND1, and FOXC2 are associated. The rate of accompanying specific genetic syndromes is low, but chromosomal abnormalities are tested for when multiple malformations are present.
The genetic basis of HLHS is highly heterogeneous, and a multifactorial inheritance model predominates. The familial recurrence risk is about 2–4% (siblings), lower than for simple Mendelian inheritance, supporting multifactorial inheritance.
NOTCH1 (9q34.3): central to aortic valve development; NOTCH1 variants are associated with part of the HLHS spectrum. NKX2.5 (5q35.1): a pan-cardiac transcription factor in heart development; variants cause various left heart malformations. HAND1 (5q33.2): a transcription factor specific to left ventricular development; left ventricular hypoplasia occurs in HAND1-deleted mice. GJA1 (Connexin 43): involved in intercellular communication in heart development; variants are associated with left heart malformations.
Among chromosomal abnormalities, HLHS frequency is high in Turner syndrome (45,X), and HLHS may also accompany 11q deletion (Jacobsen syndrome), trisomy 18, etc. However, most HLHS cases have normal chromosomes. Currently, chromosomal microarray or whole-exome sequencing is performed clinically when multiple malformations are present. Focused assessment of left heart structures during fetal echocardiography is recommended for parents of children with HLHS.
HLHS occurs at a frequency of about 1 in 8,000–10,000 births and accounts for about 2–3% of all congenital heart malformations. It is slightly more common in males (male-to-female ratio about 1.5–2:1) and occurs worldwide regardless of ethnicity or region.
Without treatment, about 25% die within the first week of life and about 95% within 1 month, making it the most lethal of the congenital heart malformations. Before the introduction of the Norwood procedure (1983), only palliative care or waiting for transplantation was possible immediately after diagnosis.
Currently, the 5-year survival of patients who have undergone staged palliative surgery is about 60–70%. Operative mortality at each stage: Norwood (stage 1) 10–20%, Glenn (stage 2) 1–5%, Fontan (stage 3) 1–3%. Survival at 10–15 years after Fontan is about 80–90%, but long-term complications of single-ventricle physiology accumulate.
In Korea, the number of patients registered for Special Copayment Reduction (V147) is gradually increasing, and staged surgery is performed at a small number of large pediatric cardiac centers. A specialized adult congenital heart care system is being established for HLHS-Fontan patients who have reached adulthood.
Because a normally functioning left heart is absent in HLHS, all systemic blood flow is supported by the right ventricle (single ventricle). In fetal life, the systemic circulation can be maintained through the patent foramen ovale and ductus arteriosus, but when the ductus begins to close after birth, systemic blood flow decreases sharply and shock develops.
Hemodynamics of HLHS after birth: ① The right ventricle ejects blood into the pulmonary artery. ② From the pulmonary artery, blood flows through the ductus arteriosus (PDA) into the systemic circulation (aorta), retrogradely. ③ The ascending aorta receives only retrograde flow, so the coronary arteries are also perfused retrogradely. ④ Blood oxygenated in the lungs mixes into the right atrium via the pulmonary veins → left atrium → foramen ovale or atrial septal defect.
In this mixed circulation, the balance between systemic (Qs) and pulmonary (Qp) circulation is clinically very important. When pulmonary vascular resistance is high, pulmonary blood flow is low (Qp/Qs < 1) and cyanosis worsens; when pulmonary vascular resistance is low, pulmonary blood flow is excessive (Qp/Qs > 1), the systemic circulation is insufficient, and metabolic acidosis develops. Keeping the ductus arteriosus open with prostaglandin E1 (PGE1) is key to survival.
Purpose of each surgical stage: Norwood (stage 1) — reconstructs the main pulmonary artery into a neo-aorta and provides pulmonary blood flow via a BTS or Sano conduit. Glenn (stage 2, performed at 4–6 months) — connects the superior vena cava (SVC) directly to the pulmonary artery (BDG) to provide passive pulmonary blood flow. Fontan (stage 3, performed at 2–3 years) — also connects the inferior vena cava (IVC) to the pulmonary artery so that all systemic venous blood passes through the lungs, eliminating the mixed circulation and completing single-ventricle Fontan physiology.
The presentation of symptoms in HLHS differs greatly by treatment stage.
Neonatal period (before treatment): at birth the infant may appear relatively stable because of the patent ductus arteriosus and foramen ovale, but when the ductus begins to close spontaneously within hours to days after birth, systemic blood flow decreases sharply. The main symptoms are progressively worsening cyanosis, lethargy, feeding refusal, tachypnea, pallor, cold extremities, and shock. Without treatment, the condition deteriorates rapidly and leads to death.
After the Norwood procedure (stage 1): complete mixing circulation persists, so some cyanosis remains. Maintaining the balance between hypoxemia and heart failure is important. Sudden deterioration can occur during the vulnerable postoperative period (inter-stage period), so home monitoring is needed.
After the Glenn procedure (stage 2): the superior vena cava is connected to the pulmonary artery, so upper-body venous blood passes through the lungs, but lower-body venous blood still mixes in the atrium. Cyanosis decreases but does not disappear completely.
After the Fontan procedure (stage 3, long term): cyanosis mostly resolves. However, long-term complications of single-ventricle Fontan physiology accumulate: exercise intolerance, arrhythmias (atrial flutter, atrial fibrillation, sinus node dysfunction), protein-losing enteropathy (PLE), plastic bronchitis, liver fibrosis (Fontan-associated liver disease, FALD), and Fontan circulatory failure (Fontan failure).
Neonatal physical findings: characterized by generalized cyanosis, pale and cold extremities, rapid and weak pulses, prolonged capillary refill time (>3 seconds), and hypotension. When the ductus arteriosus is sufficiently patent, pulses may be transiently well palpable. On cardiac auscultation a systolic or nonspecific murmur may be heard, but in severe cases there may be no murmur. A single second heart sound (S2) (pulmonary component only) is characteristic.
Keeping the ductus arteriosus open with PGE1 improves limb pulses and relieves cyanosis. However, PGE1 can lower pulmonary vascular resistance and cause excessive pulmonary blood flow, so monitoring of hemodynamic balance is needed.
Long-term findings after the Fontan procedure: as Fontan circulatory failure progresses, ascites, lower-limb edema, and jugular venous distension appear. Protein-losing enteropathy (PLE) is accompanied by generalized edema, hypoalbuminemia, and diarrhea. Liver fibrosis (FALD) promotes hepatomegaly and increased liver stiffness. When arrhythmias occur, palpitations, presyncopal symptoms, and syncope appear.
Laboratory findings: neonatal metabolic acidosis (elevated lactate) and hypoxemia. In Fontan patients, low serum albumin, abnormal liver function, and elevated BNP are observed.
Fetal echocardiography: prenatal diagnosis of HLHS is very important for improving prognosis. When a very small left ventricle or abnormal left heart structures are found on the four-chamber view during the standard prenatal ultrasound at 18–22 weeks of gestation, fetal echocardiography is performed immediately. Fetal echocardiography assesses left ventricular size, the status of the mitral and aortic valves, ascending aortic diameter, coronary blood flow, and associated malformations. Upon prenatal diagnosis, a final delivery plan (delivery at a cardiac specialty center, readiness for immediate PGE1 administration) is established and parents are counseled.
Pulse oximetry newborn screening: on pulse oximetry screening performed 24–48 hours after birth, SpO2 <95% or an upper-lower limb SpO2 difference ≥3% raises suspicion of a congenital heart malformation, and echocardiography is performed. Most HLHS cases show abnormal results on SpO2 screening.
Management after prenatal diagnosis: when HLHS is diagnosed prenatally, a predelivery plan is established with a multidisciplinary team including the pediatric cardiology team, neonatal intensive care specialists, pediatric cardiac surgeons, genetic counselors, and social workers. The option of terminal care is also fully discussed with the parents.
Echocardiography: the standard for diagnosing HLHS and preoperative evaluation. Left ventricular size (z-score ≤-2), mitral atresia/stenosis, aortic atresia/stenosis, ascending aortic diameter (1/3 of normal or less), ductal status, and restriction of the foramen ovale are assessed. Assessment of right ventricular function is also important for surgical planning and prognostic prediction.
Cardiac CT angiography: used before the Norwood procedure to delineate pulmonary artery anatomy (size of the left and right pulmonary arteries, branch abnormalities), aortic arch anatomy (presence of coarctation), and BTS/Sano conduit position in three dimensions.
Cardiac MRI: used after the Glenn procedure for pulmonary vascular anatomy, assessment of the Fontan circuit, and precise measurement of right ventricular function.
Cardiac catheterization: measurement of pulmonary vascular resistance (PVR) before the Fontan procedure is essential. PVR <3 Wood units/m² (or mean pulmonary artery pressure <15 mmHg) is the criterion for Fontan suitability. Follow-up catheterization after Fontan assesses Fontan circuit pressure, systemic venous pressure, and right ventricular function.
Genetic testing: chromosomal microarray or whole-exome sequencing is performed when multiple malformations are present.
There are currently two strategies for treating HLHS: ① staged palliation and ② cardiac transplantation. Most centers use staged surgery as the primary strategy.
Emergency neonatal stabilization: immediately upon diagnosis, the ductus arteriosus is kept open with a continuous intravenous infusion of PGE1 (alprostadil) 0.05–0.1 μg/kg/min. Nasal cannula oxygen lowers pulmonary vascular resistance and causes excessive pulmonary blood flow, so Qp/Qs is instead kept balanced with room air or inhaled nitrogen mixtures. Correction of metabolic acidosis, maintenance of blood pressure, and prevention of hypothermia are essential.
Stage 1: Norwood procedure (days to weeks after birth): a neo-aorta is reconstructed using the main pulmonary artery and anastomosed to the hypoplastic native aorta. To supply pulmonary blood flow, a modified Blalock-Taussig shunt (m-BTS: right subclavian artery → right pulmonary artery Gore-Tex conduit) or the Sano modification (right ventricle → pulmonary artery conduit) is performed. Operative mortality 10–20%.
Stage 1.5 (optional): bidirectional Glenn + Norwood modification: performed at some centers as an intermediate procedure between stages 1 and 2.
Stage 2: bidirectional Glenn procedure (4–6 months of age): the superior vena cava (SVC) is anastomosed directly to the right pulmonary artery so that upper-body venous blood passes passively through the lungs. The BTS/Sano conduit is removed to reduce single-ventricle preload. Operative mortality 1–3%.
Stage 3: Fontan procedure (2–4 years): the inferior vena cava (IVC) is connected to the right pulmonary artery with an extracardiac conduit or lateral tunnel so that all systemic venous blood passes through the lungs (completing single-ventricle Fontan physiology). Operative mortality 1–3%.
In Fontan failure or progression: heart transplantation: the final option for Fontan complications such as right ventricular dysfunction, PLE, and refractory arrhythmias. Shortage of donor hearts is the main limiting factor.
Drug therapy: Fontan patients need anticoagulation (aspirin or warfarin), heart failure treatment (ACE inhibitors, β-blockers), and additional drugs depending on Fontan complications.
HLHS is the most lethal of the congenital heart malformations, but survival continues to improve with advances in staged palliative surgery.
Survival by stage: 30-day survival after the Norwood procedure is 80–90% at specialty centers. 30-day survival after the Glenn procedure is 97–99%. 30-day survival after the Fontan procedure is 97–99%. After the Fontan procedure, 5-year survival is 80–90%, 10-year survival 70–80%, and 15-year survival about 60–70%.
Long-term complications: Fontan circulatory failure (Fontan failure) is the main cause of long-term death. Arrhythmias after Fontan (30-year cumulative incidence over 50%), protein-losing enteropathy (PLE, 10–15%/15 years), plastic bronchitis (1–5%), Fontan-associated liver disease (FALD, mild liver fibrosis in almost all), thrombosis/embolism (0.5–2% per year), neurodevelopmental abnormalities (cognitive, learning, and behavioral problems, 50–70%).
Adult HLHS-Fontan patients: currently a growing and important patient group in adult congenital heart clinics. Apart from heart transplantation there is no definitive correction, so continued follow-up and management of complications are needed.
Primary prevention of HLHS itself is currently not possible. Fetal echocardiographic screening is recommended when there is a family history (history of HLHS or left heart malformation in a first-degree relative).
Prenatal diagnosis by fetal echocardiography: prenatal diagnosis allows planned delivery (delivery at a cardiac specialty center with the pediatric cardiology team on standby), minimizing the period of neonatal hypoxemia and shock. There are reports that survival of prenatally diagnosed patients is higher than that of patients diagnosed postnatally.
PGE1 readiness immediately after delivery: newborns prenatally diagnosed with HLHS are given PGE1 immediately after birth to keep the ductus arteriosus open.
Home monitoring after the Norwood procedure: during the vulnerable inter-stage period between Norwood and Glenn, SpO2 and weight are monitored daily at home to detect sudden deterioration (SpO2 <75%, weight loss) early.
Prevention of Fontan complications: the onset of complications is delayed through regular follow-up (echocardiography every 6–12 months, planned annual cardiac catheterization), anticoagulation, exercise rehabilitation, and vaccination (influenza, pneumococcus).
Norwood WI, Lang P, Casteneda AR, Campbell DN. Experience with operations for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 1981;82(4):511-519. PMID: 7277543.
Tweddell JS, Hoffman GM, Mussatto KA, et al. Improved survival of patients undergoing palliation of hypoplastic left heart syndrome. Circulation. 2002;106(12 Suppl 1):I82-I89. PMID: 12354718.
Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971;26(3):240-248. DOI: 10.1136/thx.26.3.240. PMID: 5089489.
Mahle WT, Spray TL, Wernovsky G, et al. Survival after reconstructive surgery for hypoplastic left heart syndrome. Circulation. 2000;102(19 Suppl 3):III136-III141. DOI: 10.1161/01.CIR.102.suppl_3.III-136. PMID: 11082381.
Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. DOI: 10.1093/eurheartj/ehaa554. PMID: 32860028.
Ohye RG, Sleeper LA, Mahony L, et al. Comparison of shunt types in the Norwood procedure for single-ventricle lesions (PCMB trial). N Engl J Med. 2010;362(21):1980-1992. DOI: 10.1056/NEJMoa0912461. PMID: 20505177.
Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153(6):807-813. DOI: 10.1016/j.jpeds.2008.05.059. PMID: 18657826.
Rychik J. Hypoplastic left heart syndrome: from in-utero diagnosis to school age. Semin Fetal Neonatal Med. 2005;10(6):553-566. DOI: 10.1016/j.siny.2005.07.003. PMID: 16202659.
Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437(7056):270-274. DOI: 10.1038/nature03940. PMID: 16025100.
Warnes CA. Fontan operation: the adult patient perspective. J Am Coll Cardiol. 2021;77(22):2861-2872. DOI: 10.1016/j.jacc.2021.03.323. PMID: 34045025.